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Adherence and outcomes to direct oral
anticoagulants among patients with atrial
fibrillation: findings from the veterans
health administration
Ryan T. Borne1* , Colin O’Donnell2, Mintu P. Turakhia3,4, Paul D. Varosy1,2, Cynthia A. Jackevicius5,
Lucas N. Marzec1, Frederick A. Masoudi1, Paul L. Hess1,2, Thomas M. Maddox6 and P. Michael Ho1,2
Abstract
Background: The direct oral anticoagulants (DOACs) reduce the risk of stroke in moderate to high-risk patients
with non-valvular atrial fibrillation (AF). Yet, concerns remain regarding its routine use in real world practice. We
sought to describe adherence patterns and the association between adherence and outcomes to the DOACs
among outpatients with AF.
Methods: We performed a retrospective cohort study of patients in the VA Healthcare System who initiated
pharmacotherapy with dabigatran, rivaroxaban, or apixaban between November 2010 and January 2015 for non-
valvular AF with CHA2DS2-VASc score ≥ 2. Adherence was determined using pharmacy refill data and estimated by
the proportion of days covered (PDC) over the first year of therapy. Clinical outcomes, including all-cause mortality
and stroke, were measured at 6 months and used to assess measures of adherence for each DOAC.
Results: A total of 2882 patients were included. Most were prescribed dabigatran (72.7%), compared with rivaroxaban
(19.8%) or apixaban (7.5%). The mean PDC was 0.84 ± 0.20 for dabigatran, 0.86 ± 0.18 for rivaroxaban, and 0.89 ± 0.14
for apixaban (p < 0.01). The proportion of non-adherent patients, PDC <0.80, was 27.6% for all and varied according
DOAC. Lower adherence to dabigatran was associated with higher risk of mortality and stroke (HR 1.07; 1.03–1.12 per 0.
10 decline in PDC).
Conclusions: In a real-world VA population being prescribed anticoagulation for AF, more than one quarter had sub-
optimal adherence. Lower adherence was associated with a higher risk of mortality and stroke. Efforts identifying non-
adherent patients, and targeted adherence interventions are needed to improve outcomes.
Keywords: Medication adherence, Atrial fibrillation, Direct oral anticoagulants
Background
Atrial fibrillation (AF) is the most common cardiac
arrhythmia, with around 5 million new cases each year
[1]. Anticoagulation significantly reduces the incidence
of clinical stroke and mortality among patients with AF
at moderate to high risk of thromboembolic events
(CHA2DS2-VASc ≥2) [2]. Based on the results of mul-
tiple randomized controlled trials (RCTs), the direct oral
anticoagulants (DOACs) are now frequently used to
reduce this risk [3–5]. Additionally, they have demon-
strated favorable risk-benefit profiles compared to war-
farin with significant reductions in stroke, intracranial
hemorrhage, and mortality [6].
While decades of knowledge have demonstrated the
safety and efficacy of warfarin, less is known about how
the DOACs have been adopted into routine clinical care.
Furthermore, concerns remain about DOACs because of
their shorter half-lives and the potential for reductions
in effectiveness with poor adherence. Because of the lack
of laboratory monitoring to assess therapeutic levels, it
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is important to assess adherence to DOACs and the
extent to which it varies by patient characteristics and
different DOACs currently available. The VA health care
system, being the largest integrated healthcare system
with an anticoagulation infrastructure and standard
copayments, offers a unique opportunity to examine
real-world adherence under ideal conditions.
Accordingly, we evaluated adherence patterns to the
three approved DOACs (as of January 2015) and the
association between adherence with outcomes among
patients with AF and prescribed DOACs in the VA
Healthcare System. Specifically, we sought to
characterize adherence using portion of days covered
(PDC) to dabigatran, rivoraxaban, and apixaban separ-
ately. Second, we assessed the patient level factors asso-
ciated with nonadherence. Finally, we assessed the
association between lower adherence and outcomes of
stroke and mortality for each of the DOACs.
Methods
Study design
We performed a retrospective cohort study of patients
in the VA Healthcare System who initiated pharmaco-
therapy with dabigatran, rivaroxaban, or apixaban
between November 2010 and January 2015 for non-
valvular AF with CHA2DS2-VASc score ≥ 2. Given its
recent approval, edoxaban was not included in this study
due to the time during which this analysis was per-
formed. Patients were included who had the earliest
DOAC prescription in November 2010 and those who
were on warfarin from June, 2006. Patients with AF or
atrial flutter were identified from the VA Corporate Data
Warehouse medical files through a principal or second-
ary diagnosis of AF (ICD-9 code 427.3, 427.31, 427.32).
Patients could have been taking warfarin previously and
switched to a DOAC, or started on a DOAC de novo.
Because we were interested in assessing adherence
behavior to DOACs, we excluded patients with less than
1 year follow-up after starting a DOAC, patients who
initiated a DOAC and then crossed over to warfarin, and
patients who were started on 2 or more different
DOACs during follow-up.
Medication adherence
Adherence to each DOAC was calculated in the first
year of therapy. Adherence was measured using the
proportion of days covered (PDC), which is a
validated measure previously correlated with DOAC
outcomes [3, 4]. The PDC was defined as the number
of doses dispensed in relation to the dispensing
period. [5, 6] The numerator was based on the
prescription fill dates and number of pills dispensed
to determine the number of outpatient days for which
each DOAC was supplied. Patients were considered
adherent if they achieved a PDC > 80%, a commonly
used standard [7]. As a sensitivity analysis, differences
in DOAC adherence stratified by prior warfarin use
was also evaluated.
Mortality and stroke
We assessed a composite of all-cause mortality and
stroke as the primary outcome of interest. Mortality was
obtained through the VA Vital Status File, which
compiles data from the Beneficiary Identification Records
Locator Subsystem Death File, VA Medicare Vital Status
File, and the Social Security Administration Death
Master File. Stroke (ischemic and hemorrhagic) was
obtained using previously validated primary or
secondary International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) diagnostic
codes (346.60, 346.61, 346.62, 346.63, 431, 433.01,
433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11,
434.91, 997.02) [8].
Statistical analysis
Testing for differences in the proportions of dichotom-
ous covariates across the 3 DOAC drugs were calculated
with the network algorithm of Mehta and Patel, rather
than the less efficient Freeman-Halton extension to
2 × 3 tables of the Fisher exact test. The one-way
analysis of variance Savage score was used to test for
differences in location for the continuous covariates. A
Generalized Estimating Equation (GEE) logistic regres-
sion with adjustment for risk factors and a term to
adjust for patients clustered within hospitals was used to
evaluate the interaction of prior warfarin use vs. de novo
treatment with DOAC type and to determine significant
risk factors for the outcome of nonadherence. Similarly,
a GEE linear model was used to determine the inter-
action effect of prior warfarin use on PDC at one year.
Cox proportional hazards models adjusted for patient
risk factors (heart failure, age, diabetes, stroke/transient
ischemic attack, vascular disease, sex, coronary artery
disease), and a term for patients within hospital (frailty,
a standard statistical term in time to event analyses indi-
cating adjustment for correlated random effects), were
used to assess measures of PDC at 6 months and nonad-
herence at 6 months on the combined endpoint of mor-
tality and/or stroke for each DOAC. The results for
mortality and stroke for apixaban were not included due
to the low event rate.
All analyses were performed using SAS9.4 TS Level
1 M3 software, © 2002–2012 by SAS Institute Inc., Cary,
NC, USA. The Colorado Multiple Institutional Review
board approved this study and waiver of informed con-
sent was granted. The authors are solely responsible for
the design and conduct, drafting, and editing of this
manuscript and its contents.
Borne et al. BMC Cardiovascular Disorders  (2017) 17:236 Page 2 of 7
Results
Over the study period, a total of 10,279 patients were
started on DOACs. After excluding patients with less
than 1-year follow-up period (n = 3111), those who
were prescribed more than 1 DOAC during the study
period (n = 872), those who were prescribed warfarin
after DOAC initiation (n = 1446) and those with
CHA2DS2-VASc score < 2 (n = 1968), a total of 2882
patients were included in the analysis (Fig. 1).
Baseline patient characteristics are described in
Table 1. The mean age of the cohort was 67.4 ± 9.5,
most whom were white (82.7%) and male (96.9%).
Co-morbidities included hypertension (88.7%),
diabetes mellitus (48.5%), congestive heart failure
(29.6%), cerebrovascular disease (11.1%), and prior
myocardial infarction (13.6%). The mean and median
CHA2DS2-VASc score were 2.9 ± 1.1 and 3 (IQR 2–3),
respectively. Most patients in the cohort were prescribed
dabigatran (72.7%), compared with rivaroxaban (19.8%) or
apixaban (7.5%). Differences in patient level character-
istics between DOACs were largely similar with
significant differences seen in age (mean age among
patients prescribed dabigatran 66.9 vs. 73.1 for
apixaban), rate of hypertension (89.4% for dabigatran
vs. 83.3% for apixaban), and CHA2DS2-VASc score
(2.89 for dabigatran vs. 3.2 for apixaban).
The mean PDC was 0.84 ± 0.20 for dabigatran,
0.86 ± 0.18 for rivaroxaban, and 0.89 ± 0.14 for apixaban
(p < 0.01) (Table 1). The proportion of non-adherent
patients, defined as PDC <0.80, was 28.8%, 25.0%, 22.8%
respectively (p = 0.05). Adherence using PDC stratified
by patients who had previously been on warfarin and
those who were started de novo are described in
Table 2. There was a statistically significant small
difference in PDC between drug types and history of
prior warfarin use (P < 0.01). Based on PDC <80%
for nonadherence, there was no statistically significant
difference between drug types and history of prior
warfarin use (P = 0.44).
Table 3 describe factors associated with nonadher-
ence, where an odds ratio of >1 is associated with
greater nonadherence and an odds ratio < 1 is associ-
ated with greater adherence. Age in years (OR, 0.98;
95% CI, 0.96–0.99; p < 0.01), hypertension (OR, 0.69;
95% CI, 0.49–0.99; p = 0.04), diabetes (OR, 0.57; 95%
CI, 0.41–0.79; p < 0.01), and stroke (OR, 0.36; 95%
CI, 0.2–0.68; p < 0.01) were associated with greater
adherence.
The combined end-point of mortality and/or stroke
based on adherence patterns are described in Table 4.
The total number of follow-up days was 1,922,857,
with mean (SD) and median (IQR) of 667.2 (432.2)
and 582 (388, 933), respectively. The overall rate of
death and stroke were 17.4% (502) and 1.7% (49),
respectively.
Among patients on dabigatran, there was a significant
association between lower adherence (per 0.1 decline in
PDC measured over the initial 6 months after initiation
of therapy) and higher risk of death or stroke; (HR, 1.07;
95% CI, 1.03–1.12; per 0.1 drop in the PDC; p < 0.01;
n = 277 total events; death = 253, stroke = 24). Among
patients on rivaroxaban, there was a trend for an associ-
ation between lower adherence at 6 months (per 0.1
decline in PDC) and higher risk of mortality and stroke
(HR, 1.07; 95% CI, 0.89–1.28; p = 0.46; n = 25 total
events; death = 24, stroke = 1]. In secondary analysis,
nonadherence (PDC <80%) at 6 months to dabigatran
was associated with increased risk of death or stroke
(HR, 1.54; 95% CI, 1.20–1.97; p < 0.01). There was a
similar trend for rivaroxaban but it was not statistically
significant (HR, 1.74; 95% CI, 0.77–3.94; p = 0.18). Out-
comes analyses were not conducted for apixaban due to
the small number of events (n = 5).
Discussion
Using VHA data from June 2006 to January 2015, we
characterized adherence to DOACs and assessed the
association between nonadherence and outcomes among
patients in the VA Healthcare System. There were three
main findings. First, 1 in 4 patients had sub-optimal
adherence, which varied slightly based on the DOAC.
Second, several patient factors were associated with
greater medication adherence, including older age, dia-
betes, and stroke. Third, nonadherence was associated
with adverse outcomes including mortality and stroke
for dabigatran, with a similar trend for rivoraxaban.
Fig. 1 Flow Diagram of patient inclusion and exclusion
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Medication nonadherence is a prevalent and growing
concern among healthcare providers. Previous investiga-
tions have described adherence patterns to dabigatran.
Using the Danish National Prescription Registry, Gorst-
Rasmussen evaluated 2960 patients started on dabiga-
tran for AF [9]. The mean one-year PDC was 0.84 and
about one-quarter of patients were nonadherent (PDC
<80%). Among 17,000 patients on dabigatran, PDC
among de novo starters were 0.67 and 0.71 for those
previously on warfarin [10]. Schulmann interviewed a
small cohort of patients (103) and found that 88% of
patients were adherent (PDC >80%) to dabigatran [11].
The VA Healthcare System offers a unique opportunity
to examine real-world adherence under ideal conditions.
It is the largest integrated healthcare system and has
specific processes of care by which anticoagulation is
safely administered (including anticoagulation clinics
and a clinical pharmacist infrastructure). Additionally,
copayments are standard across oral anticoagulation
agents which does not lead to a differential copayment
burden. A previous investigation in the VA population
demonstrated that 27.8% of patients on dabigatran for
AF were nonadherent, which was also associated with an
increased risk for all-cause mortality and stroke [8]. Our
findings further this knowledge by demonstrating that
nonadherence is common, even among the newer
DOACs. Furthermore, these findings are in direct
discordance with adherence patterns seen in randomized
controlled trials which are generally higher. Differences
in adherence patterns between clinical trials and routine
clinical practice are multifactorial and include a potential
Hawthorne effect for those enrolled in clinical trials and
lack of close follow up, high incidence of comorbidities
and polypharmacy, and/or financial constraints for those
in routine clinical care. Additional research is needed to
determine which factors can be targeted to maximize
patient outcomes.
Predictors of greater adherence included older age
and a history of hypertension, diabetes, and stroke.
Factors previously known to be associated with non-
adherence include male gender, homelessness, and
psychiatric disorders, particularly depression while
those associated with greater adherence include high
level of education, stability of family background, and
affordability to therapy [12–15]. Additionally, treat-
ment of asymptomatic disease is associated with poor
adherence [15]. Importantly, cardiovascular disease,
such as in some cases of atrial fibrillation, are gener-
ally asymptomatic chronic diseases where the
perceived benefits of daily medical therapy may not
be apparent to patients. Among these patients,
physicians should have a heightened awareness of the
possibility of poor adherence and consider directly
asking patients about their adherence.
Table 1 Baseline characteristics among patients being prescribed DOACs
Patient Characteristics All n = 2882 Dabigatran
n = 2096 (72.7%)
Rivaroxaban
n = 571 (19.8%)
Apixaban
n = 215 (7.5%)
p
Age (mean + SD) 67.4 (9.5) 66.9 (9.3) 67.3 (9.7) 73.1 (8.8) <0.01
Male (%) 2792 (96.9) 2035 (97.1) 552 (96.7) 205 (95.4) 0.32
White Race (%) 2383 (82.7) 1735 (82.8) 467 (81.8) 181 (84.2) 0.72
Hypertension (%) 2556 (88.7) 1874 (89.4) 503 (88.1) 179 (83.3) 0.03
Congestive Heart Failure (%) 852 (29.6) 624 (29.8) 173 (30.3) 55 (25.6) 0.41
Diabetes Mellitus (%) 1398 (48.5) 1036 (49.4) 270 (47.3) 92 (42.8) 0.15
Cerebrovascular Accident (%) 321 (11.1) 240 (11.5) 63 (11.0) 18 (8.4) 0.41
Prior Myocardial Infarction (%) 391 (13.6) 269 (12.8) 89 (15.6) 33 (15.4) 0.16
Peripheral Arterial Disease (%) 280 (9.7) 201 (9.6) 53 (9.3) 26 (12.1) 0.45
Peripheral Arterial Disease (%) 2.9 (1.1) 2.9 (1.0) 3.0 (1.1) 3.2 (1.2) <0.01
CHA2DS2-VASc (mean + SD) 2.9 (1.1) 2.9 (1.0) 3.0 (1.1) 3.2 (1.2) <0.01
Adherence
Mean (SD) pill count per
dispensed supply
38.1 (20.9) 38.2 (20.8) 38.2 (22.0) 36.4 (18.7) <0.01
Proportion of Days Covered
(mean + SD)
0.85 (0.19) 0.84 (0.20) 0.86 (0.18) 0.89 (0.14) <0.01
PDC < 80% n (%) 796 (27.6%) 604 (28.8%) 143 (25.0%) 49 (22.8%) 0.05
Table 2 Adherence patterns among patients previously on
warfarin and those started de novo
Dabigatran Rivaroxaban Apixaban p
De novo
(Mean, SD)
0.84 (0.20) 0.87 (0.19) 0.87 (0.15) <0.01
Prior warfarin
use (Mean, SD)
0.84 (0.19) 0.86 (0.18) 0.89 (0.14) <0.01
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Adherence to DOACs was a significant predictor of
outcomes including all-cause mortality and stroke. A
similar association of risk of death or stroke was seen
among the 27.8% of non-adherent patients on dabiga-
tran, with a hazard ratio of 1.13 (95% CI 1.07–1.19) [8].
Furthermore, prior studies have shown similar associa-
tions of risk and nonadherence among patients with
coronary artery disease, heart failure, hypertension, and
hyperlipidemia [16–19]. For example, among 10,000
patients with diabetes, 21% were non-adherent which
was associated with an increased risk for all-cause
hospitalization and mortality [16]. These findings sug-
gest that medication nonadherence is common among
many chronic illnesses and highly impacts outcomes.
There are a few implications of these findings. First,
while adherence was significantly different stratified by
DOAC, the absolute difference was very small. Similarly,
differences in demographic and co-morbidities associ-
ated with nonadherence were small and determining
nonadherence to DOACs based on these clinical charac-
teristics may be difficult. This suggests that other mech-
anisms to detect patients at risk for nonadherence need
to be identified, including directly asking patients about
adherence or utilizing data systems in which prescription
refills, or lack thereof, are recorded and provided in real-
time. Further evaluation of such data systems should be
developed to determine if they can successfully be
implemented and improve patient adherence. Addition-
ally, it is often thought that adherence to medical
therapy improves with simplification; however, we found
that adherence to the once daily rivaroxaban did not
have better adherence rate. Further studies are needed
to evaluate this perception.
Certain factors should be considered in the interpret-
ation of this study. First, our analysis was confined to
patients in the VA Healthcare System with the clear
majority of patients being white males. Thus, our results
may not apply to the broader population of patients
being prescribed DOACs. However, the VA provides an
opportunity to examine adherence in a closed pharmacy
system with highly reliable data sources because refill
data for these medications are well captured given the
smaller copay in the VA. Second, while we utilized phar-
macy databases to capture medication dispensing, there
is a lack of distinction between dispensing and con-
sumption, making this type of analysis less reliable at the
individual level. However, refill adherence has previously
been shown to be an accurate marker of patients’ adher-
ence in the VA system [20]. Additionally, direct methods
of assessing adherence (i.e. directly observed therapy)
have limitations and are not practical for routine clinical
use. Third, there were relatively fewer patients on rivar-
oxaban and apixaban as these are newer to the VA sys-
tem and their use is dependent on contraindications or
previous intolerance to dabigatran. Therefore, broader
examination of outcomes is limited due to lack of power
given the relatively smaller sample size. Furthermore,
longer term outcomes are limited given the exclusion of
a large majority of patients who had less than one year
follow up. Additionally, the impact of longer duration of
follow up on adherence or outcomes was not addressed
but should be explored in future analysis. Fourth, direct
comparisons between classes of DOACs were not




Parameter Odds Ratio (95% CI) Odds Ratio (95% CI) Odds Ratio (95% CI) Odds Ratio (95% CI)
Age 0.98 (0.96, 0.99) 0.99 (0.97, 1.00) 0.96 (0.93, 0.99) 0.97 (0.90, 1.04)
Male 0.85 (0.54, 1.34) 0.85 (0.47, 1.53) 1.58 (0.54, 4.61) 0.26 (0.06, 1.13)
White Race 0.73 (0.59, 0.92) 0.69 (0.53, 0.90) 0.81 (0.48, 1.37) 0.61 (0.23, 1.65)
Hypertension 0.69 (0.49, 0.99) 0.74 (0.47, 1.16) 0.64 (0.27, 1.50) 0.66 (0.17, 2.61)
Congestive Heart Failure 0.74 (0.53, 1.03) 0.91 (0.61, 1.36) 0.52 (0.24, 1.13) 0.28 (0.07, 1.10)
Diabetes Mellitus 0.57 (0.41, 0.79) 0.68 (0.47, 0.97) 0.56 (0.27, 1.14) 0.15 (0.03, 0.67)
CVA 0.36 (0.20, 0.68) 0.47 (0.23, 0.94) 0.29 (0.06, 1.40) 0.11 (0.01, 1.43)
Prior Myocardial Infarction 1.20 (0.96, 1.50) 1.40 (1.07, 1.82) 0.88 (0.55, 1.39) 0.53 (0.18, 1.53)
Peripheral Arterial Disease 0.99 (0.72, 1.36) 0.96 (0.68, 1.34) 1.14 (0.60, 2.17) 1.32 (0.49, 3.54)
CHA2DS2-VASc Score 0.88 (0.76, 1.01) 0.81 (0.68, 0.97) 1.09 (0.85, 1.41) 0.81 (0.40, 1.64)
Table 4 Time fixed analysis for mortality and stroke based on
adherence
Dabigatran Rivaroxaban
HR (95% CI) p HR (95% CI) p
PDC 6 month
(per 0.1 decline)
1.07 (1.03–1.12) <0.01 1.07 (0.89–1.28) 0.46
Nonadherence 6 month 1.54 (1.20–1.97) <0.01 1.74 (0.77–3.94) 0.18
Models were adjusted for demographics and comorbidities (heart failure, age,
diabetes, stroke/transient ischemic attack, vascular disease, sex, coronary
artery disease)
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performed as we are unable to account for unmeasured
confounders and selection bias for the determination of
which DOAC was selected. Fifth, we did not evaluate
the association between adherence and bleeding given
the low rate of bleeding events. Sixth, a large portion of
patients (1446) were excluded after having been pre-
scribed warfarin after DOAC initiation. The reasons for
such were unclear from this study and further evaluation
is needed to address reasons for a change in anticoagula-
tion strategies. Finally, our results are likely an overesti-
mation of adherence based on the exclusions. For
example, by excluding patients who stopped or did not
tolerate a DOAC, we selected a group of patients more
likely to adhere to medical therapy and thus increasing
the adherence rate beyond what is seen in practice.
Conclusions
This study characterizes adherence patterns and out-
comes among patients in the VA Healthcare System
using DOACs for AF. First, more than one quarter of
patients had sub-optimal adherence with DOACs. While
there were differences in adherence between DOAC and
patient characteristics, these were not clinically signifi-
cant. Second, outcomes including all-cause mortality
and stroke were associated with medication adherence.
Efforts towards identifying non-adherent patients and
targeting adherence interventions are needed.
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